Alzheimer's Disease Therapeutics and Diagnostics: Global Markets
The global market for alzheimer’s disease reached $10.2 billion in 2012. The market is expected to decrease to $9.5 billion in 2017 for a CAGR of -1.5%.
- An overview of the global market for Alzheimer's disease therapeutic and diagnostic technologies
- Analyses of global market trends, with data from 2011 and 2012, and projections of compound annual growth rates (CAGRs) through 2017
- Review of programs in development and quantification of market opportunities
- Discussion of the market segments' economic environment, technological descriptions and issues, and applications
- Projections of usage in the major primary and secondary disease application areas
- Comprehensive company profiles of major players in the industry.
SCOPE OF REPORT
The scope of this report is on the pharmaceutical segment, diagnostics and imaging modalities. We have compiled a study of the market, and current and emerging modes of treatment. We present the market segment’s economic environment, technological descriptions and issues, applications, market factors and potential, and forecasts for 2012 to 2017. We also project usage in the major primary and secondary disease application areas. This study will be of interest to the drug industry, patients, and the medical community. It will be of interest also to suppliers of products and services to this market area.
Yogita Zutshi has worked in clinical operations and market research in pharmaceuticals, including the development of training in pharmacovigilance. She studies products, markets and regulatory environments. She holds a bachelor's degree in education, and master's degrees in clinical research and organic chemistry from Cranfield University.
Overall, the forecast for Alzheimer's disease, including disease-modifying therapeutics, therapeutics that treat related symptoms, diagnostics and imaging, is set to increase exponentially. This market was worth $8 billion in 2009 and is expected to reach $9.6 billion by 2014, a compound annual growth rate (CAGR) of 3.7%.
Diagnostics and biomarkers are expected to increase at a 5-year compound annual growth rate (CAGR) of nearly 20%. This segment was worth $1.2 billion in 2009 and is expected to reach $2.9 billion by 2014.
The imaging sector was worth $361 million in 2009 and is expected to increase at a nearly 19% compound annual growth rate (CAGR) to reach $852 million in 2014.